ME01555B - FARMACEUTSKI PREPARAT KOJI SADRŽI {lS)-1,5-ANHIDR0-1-[5-{4-ETOKSIBENZIL)-2-METOKSI-4-METILFENIL]-1- TIO-D-GLUCITOL l METFORMIN l NJEGOVE UPOTREBE U LIJEČENJU DIJABETESA - Google Patents

FARMACEUTSKI PREPARAT KOJI SADRŽI {lS)-1,5-ANHIDR0-1-[5-{4-ETOKSIBENZIL)-2-METOKSI-4-METILFENIL]-1- TIO-D-GLUCITOL l METFORMIN l NJEGOVE UPOTREBE U LIJEČENJU DIJABETESA

Info

Publication number
ME01555B
ME01555B MEP-2013-137A MEP13713A ME01555B ME 01555 B ME01555 B ME 01555B ME P13713 A MEP13713 A ME P13713A ME 01555 B ME01555 B ME 01555B
Authority
ME
Montenegro
Prior art keywords
ethoxybenzyl
glucitol
metformin
thio
methylphenyl
Prior art date
Application number
MEP-2013-137A
Other languages
English (en)
Inventor
Teisuke Takahashi
Saeko Uchida
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of ME01555B publication Critical patent/ME01555B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Predmetni pronalazak se odnosi na farmaceutske preparate koji su korisni u lečenju dijabetes melitusa, bolesti koje se dovode u vezu sa dijabetesom melitusom ili komplikacija dijabetesa melitusa, i to na  farmaceutske preparate koji sadrže kombinaciju (A) (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-D-glucitola ili njegove farmaceutski prihvatljive soli ili hidrata takvog jedinjenja ili soli; i (B) metformina.
MEP-2013-137A 2009-04-16 2010-04-16 FARMACEUTSKI PREPARAT KOJI SADRŽI {lS)-1,5-ANHIDR0-1-[5-{4-ETOKSIBENZIL)-2-METOKSI-4-METILFENIL]-1- TIO-D-GLUCITOL l METFORMIN l NJEGOVE UPOTREBE U LIJEČENJU DIJABETESA ME01555B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009100210 2009-04-16
PCT/JP2010/057196 WO2010119990A1 (en) 2009-04-16 2010-04-16 Pharmaceutical compositions
EP10764570.7A EP2419097B1 (en) 2009-04-16 2010-04-16 Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes

Publications (1)

Publication Number Publication Date
ME01555B true ME01555B (me) 2014-04-20

Family

ID=42982643

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2013-137A ME01555B (me) 2009-04-16 2010-04-16 FARMACEUTSKI PREPARAT KOJI SADRŽI {lS)-1,5-ANHIDR0-1-[5-{4-ETOKSIBENZIL)-2-METOKSI-4-METILFENIL]-1- TIO-D-GLUCITOL l METFORMIN l NJEGOVE UPOTREBE U LIJEČENJU DIJABETESA
MEP-2015-6A ME02015B (me) 2009-04-16 2010-04-16 Farmaceutski preparati sa (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi- 4-metilfenil]-1-tio-D-glucitolom i sekretagogom insulina

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2015-6A ME02015B (me) 2009-04-16 2010-04-16 Farmaceutski preparati sa (1S)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi- 4-metilfenil]-1-tio-D-glucitolom i sekretagogom insulina

Country Status (30)

Country Link
US (1) US20120040898A1 (me)
EP (3) EP2829271A3 (me)
JP (4) JP5077786B2 (me)
KR (2) KR20120016051A (me)
CN (7) CN105343880A (me)
AR (1) AR076317A1 (me)
AU (1) AU2010237748B2 (me)
BR (1) BRPI1012539A2 (me)
CA (1) CA2755392A1 (me)
CY (2) CY1114703T1 (me)
DK (2) DK2601949T3 (me)
ES (2) ES2431300T3 (me)
HK (6) HK1217301A1 (me)
HR (2) HRP20131120T1 (me)
ME (2) ME01555B (me)
MX (1) MX2011010901A (me)
MY (3) MY182720A (me)
NZ (4) NZ623838A (me)
PH (3) PH12015500235A1 (me)
PL (2) PL2601949T3 (me)
PT (2) PT2601949E (me)
RS (2) RS53056B (me)
RU (2) RU2532330C2 (me)
SG (6) SG2014012405A (me)
SI (2) SI2419097T1 (me)
SM (1) SMT201500015B (me)
TW (3) TW201500043A (me)
UA (2) UA105216C2 (me)
WO (1) WO2010119990A1 (me)
ZA (1) ZA201106727B (me)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2011039108A2 (en) 2009-09-30 2011-04-07 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TR201101809A1 (tr) * 2010-12-21 2012-07-23 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Vildagliptin ve glimepirid kombinasyonları.
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6234443B2 (ja) 2012-05-17 2017-11-22 ブイティーブイ・セラピューティクス・エルエルシー 糖尿病治療のためのグルコキナーゼ活性化因子組成物
EP2891499A4 (en) * 2012-08-30 2016-02-24 Taisho Pharmaceutical Co Ltd ASSOCIATION OF A SGLT2 INHIBITOR AND AN ANTIHYPERTENSEUR
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303098A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AU2014255727B2 (en) 2013-04-18 2019-07-25 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TW201513857A (zh) * 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
ES2869463T3 (es) * 2015-02-27 2021-10-25 Asan Found Composición para la prevención o tratamiento de la calcificación de válvulas que contiene un inhibidor de DPP-4
CN105963280B (zh) * 2016-06-30 2018-11-06 合肥华方医药科技有限公司 一种伏格列波糖口腔速溶膜及其制备方法
KR20190070956A (ko) 2016-10-19 2019-06-21 베링거 인겔하임 인터내셔날 게엠베하 Ssao/vap-1 억제제 및 sglt2 억제제를 포함하는 복합제제 및 이의 용도
EP3540072A4 (en) * 2016-11-14 2020-05-20 Kaohsiung Medical University METHOD FOR DETERMINING IF GLUCOSE METABOLISM IS ABNORMAL, AND PREVENTION AND TREATMENT THEREOF
WO2019201752A1 (en) 2018-04-17 2019-10-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
KR20190137343A (ko) 2018-06-01 2019-12-11 김유찬 계량 인덕션
MX2020008905A (es) 2018-06-12 2020-12-03 Vtv Therapeutics Llc Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
JP2003520759A (ja) 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
CN100577175C (zh) * 2001-04-04 2010-01-06 奥索-麦克尼尔药品公司 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法
ES2258141T3 (es) * 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
CN101479254B (zh) * 2006-06-29 2012-05-30 大正制药株式会社 C-苯基1-硫代山梨醇化合物
JP5194588B2 (ja) * 2006-07-06 2013-05-08 大正製薬株式会社 １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤
US8039441B2 (en) * 2006-08-15 2011-10-18 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
US20100298243A1 (en) * 2006-11-09 2010-11-25 Boehringer Ingelheim International Gmbh Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
WO2008072726A1 (ja) * 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. １－フェニル １－チオ－ｄ－グルシト－ル誘導体
PE20090603A1 (es) 2007-08-16 2009-06-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo

Also Published As

Publication number Publication date
PL2601949T3 (pl) 2015-04-30
US20120040898A1 (en) 2012-02-16
MX2011010901A (es) 2011-11-01
JP5910711B2 (ja) 2016-04-27
PT2419097E (pt) 2013-10-03
PH12019500959A1 (en) 2020-06-29
HK1217434A1 (zh) 2017-01-13
DK2419097T3 (da) 2013-10-28
JP2016104775A (ja) 2016-06-09
NZ606888A (en) 2014-07-25
ES2523408T3 (es) 2014-11-25
UA105216C2 (en) 2014-04-25
DK2601949T3 (da) 2015-01-05
HK1217435A1 (zh) 2017-01-13
CN105343060A (zh) 2016-02-24
TW201500043A (zh) 2015-01-01
MY156679A (en) 2016-03-15
CN105343871A (zh) 2016-02-24
SG175154A1 (en) 2011-11-28
SMT201500015B (it) 2015-03-05
JP6066144B2 (ja) 2017-01-25
WO2010119990A1 (en) 2010-10-21
CN105477639A (zh) 2016-04-13
SG2014014807A (en) 2014-05-29
RS53761B1 (en) 2015-06-30
CN105434430A (zh) 2016-03-30
NZ595314A (en) 2013-03-28
HRP20131120T1 (hr) 2013-12-20
EP2829271A2 (en) 2015-01-28
HRP20141080T1 (hr) 2015-01-02
EP2419097B1 (en) 2013-09-25
MY182720A (en) 2021-02-03
SG2014012462A (en) 2014-05-29
TW201103534A (en) 2011-02-01
HK1218871A1 (zh) 2017-03-17
PL2419097T3 (pl) 2014-02-28
EP2419097A1 (en) 2012-02-22
KR20120016051A (ko) 2012-02-22
SI2419097T1 (sl) 2014-01-31
HK1217302A1 (zh) 2017-01-06
RU2011146335A (ru) 2013-05-27
ME02015B (me) 2015-05-20
JP2012524710A (ja) 2012-10-18
JP2013006854A (ja) 2013-01-10
SI2601949T1 (sl) 2014-12-31
CN105343880A (zh) 2016-02-24
PT2601949E (pt) 2014-11-12
EP2601949A3 (en) 2013-09-18
ES2431300T3 (es) 2013-11-25
KR20150046382A (ko) 2015-04-29
NZ710575A (en) 2016-06-24
SG2014012405A (en) 2014-05-29
JP2015063543A (ja) 2015-04-09
PH12019500959B1 (en) 2020-06-29
PH12019500961A1 (en) 2020-08-03
RU2532330C2 (ru) 2014-11-10
AR076317A1 (es) 2011-06-01
NZ623838A (en) 2015-09-25
EP2601949B1 (en) 2014-10-29
MY183793A (en) 2021-03-16
HK1217301A1 (zh) 2017-01-06
AU2010237748A1 (en) 2011-10-20
RS53056B (en) 2014-04-30
BRPI1012539A2 (pt) 2016-03-29
HK1218881A1 (zh) 2017-03-17
CN105343059A (zh) 2016-02-24
EP2419097A4 (en) 2012-09-05
PH12019500961B1 (en) 2020-08-03
JP5660094B2 (ja) 2015-01-28
PH12015500235B1 (en) 2015-12-02
RU2014121260A (ru) 2015-12-10
AU2010237748B2 (en) 2014-10-30
PH12015500235A1 (en) 2015-12-02
UA111742C2 (uk) 2016-06-10
ZA201106727B (en) 2012-11-28
SG2014015093A (en) 2014-04-28
EP2601949A2 (en) 2013-06-12
CA2755392A1 (en) 2010-10-21
TW201622720A (zh) 2016-07-01
CY1114703T1 (el) 2016-10-05
EP2829271A3 (en) 2015-05-27
CN102395364A (zh) 2012-03-28
SG2014012553A (en) 2014-05-29
CY1115907T1 (el) 2017-01-25
JP5077786B2 (ja) 2012-11-21

Similar Documents

Publication Publication Date Title
ME01555B (me) FARMACEUTSKI PREPARAT KOJI SADRŽI {lS)-1,5-ANHIDR0-1-[5-{4-ETOKSIBENZIL)-2-METOKSI-4-METILFENIL]-1- TIO-D-GLUCITOL l METFORMIN l NJEGOVE UPOTREBE U LIJEČENJU DIJABETESA
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
WO2007122580A3 (en) Compositions of phenylephrine useful for treatment of respiratory illness
BRPI0517701A8 (pt) métodos de tratamento de diabetes mellitus
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2008000592A1 (es) Compuestos derivados de pirrol sustituido, supresores de la secrecion de acidos; composicion farmaceutica; y uso en el tratamiento o profilaxis en enfermedades tales como ulcera peptica, gastritis, esofagitis, entre otras.
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CL2007003686A1 (es) Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
NO20084924L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
GT201200164A (es) "nuevos compuestos de espiropiperidina"
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
WO2006072458A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
EA201201623A1 (ru) Лечение диабета 2 типа
CO6270306A2 (es) Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo
WO2007130825A3 (en) Fused heterocyclic compounds and their use as mglur5 modulators
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
DE602007014206D1 (de) Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
WO2008098985A3 (en) Pharmaceutical composition for the treatment of il-8 mediated diseases
NO20074536L (no) Anvendelse av jern (III)-komplekssammensetninger
EA201000392A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция